AbCellera Biologics Inc. (ABCL) Social Stream
ABCELLERA BIOLOGICS INC (ABCL) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ABCL.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 4 | $55 | $25 | $45.25 | $13.52 | 234.69% |
| 2021-12-05 | 5 | $53 | $25 | $40.8 | $13.52 | 201.78% |
| 2021-12-19 | 7 | $53 | $25 | $39.833 | $13.52 | 194.62% |
| 2021-12-21 | 7 | $53 | $25 | $38 | $13.52 | 181.07% |
| 2022-02-11 | 5 | $45 | $25 | $33 | $13.52 | 144.08% |
| 2022-02-25 | 5 | $40 | $20 | $30 | $13.52 | 121.89% |
| 2022-05-09 | 5 | $40 | $20 | $29.6 | $13.52 | 118.93% |
| 2022-05-11 | 5 | $32 | $14 | $24.8 | $13.52 | 83.43% |
| 2022-08-09 | 5 | $32 | $14 | $23.6 | $13.52 | 74.56% |
| 2022-08-11 | 5 | $34 | $14 | $24 | $13.52 | 77.51% |
| 2022-10-23 | 5 | $34 | $13 | $23.8 | $13.52 | 76.04% |
| 2022-11-02 | 4 | $34 | $13 | $23.6 | $13.52 | 74.56% |
| 2022-11-09 | 5 | $32 | $20 | $23.6 | $13.52 | 74.56% |
| 2022-11-16 | 6 | $32 | $20 | $24.5 | $13.52 | 81.21% |
The Trend in the Analyst Price Target
ABCL's average price target has moved down $20.9 over the prior 15 months.
Over the past 49 weeks, ABCL's average upside potential has been 180.06%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-02-11 | 5 | 45 | 25 | 33.0 | 9.64 | 242.32% |
| 2022-02-25 | 5 | 40 | 20 | 30.0 | 8.93 | 235.95% |
| 2022-02-28 | 5 | 40 | 20 | 29.6 | 8.71 | 239.84% |
| 2022-10-23 | 5 | 34 | 13 | 23.8 | 10.31 | 130.84% |
| 2022-11-09 | 5 | 32 | 20 | 23.6 | 11.81 | 99.83% |
ABCL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 31 weeks, ABCL's average broker recommendation rating improved by 0.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- ABCELLERA BIOLOGICS INC's variance in analysts' estimates is lower than -1455.25% of all US stocks.
- To contextualize these metrics, consider that out of stocks in the large market cap category, ABCELLERA BIOLOGICS INC's number of analysts covering the stock is greater than 149.01% of them.
- To contextualize these metrics, consider that out of stocks in the large market cap category, ABCELLERA BIOLOGICS INC's upside potential (average analyst target price relative to current price) is higher than 1773.94% of them.
- In terms of how ABCELLERA BIOLOGICS INC fares relative to stocks in the large market cap category, note that its average analyst price target is higher than 340.24% of that group.
In the Pharmaceutical Products industry, CGC, TLRY, and BLUE are the three stocks most similar to ABCELLERA BIOLOGICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
What is the outlook for ABCL? Use POWR Ratings for clearer insight into price direction.